{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:37:32Z","timestamp":1779143852110,"version":"3.51.4"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin\/chitosan nanoparticles (ccNPs) for oral delivery of RXF in order to enhance the oral bioavailability. RXF-loaded ccNPs (RXF-ccNPs) were prepared by cyclodextrin inclusion followed by complexation with chitosan. RXF-ccNPs were fully characterized by particle size, morphology and in vitro drug release. The oral delivery efficacy and transepithelial transport potential were evaluated by pharmacokinetics, in situ single-pass intestinal perfusion, cellular uptake and ex vivo imaging. The resulting RXF-ccNPs were around 165 nm in particle size with a narrow distribution. The oral bioavailability of RXF was enhanced by 2.6 folds through ccNPs compared to RXF suspensions in rats. It was shown that RXF-ccNPs could improve the intestinal permeability of RXF, increase the cellular uptake of RXF and facilitate its transport across the absorptive epithelia. The results indicate that our developed ccNPs based on sulfobutylether-\u03b2-cyclodextrin and oligochitosan are a promising vehicle to orally deliver poorly water-soluble drugs over and above RXF.<\/jats:p>","DOI":"10.3390\/pharmaceutics10030076","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T10:53:33Z","timestamp":1530183213000},"page":"76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Raloxifene\/SBE-\u03b2-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement"],"prefix":"10.3390","volume":"10","author":[{"given":"Zaihua","family":"Wang","sequence":"first","affiliation":[{"name":"Guangzhou Guocaoxiafang Biotechnology Co. Ltd., No. 3 Luoxuan 4th Road, Guangzhou International Biotech Island, Guangzhou 510320, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, No. 601 West Huangpu Avenue, Jinan University, Guangzhou 510632, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/OGX.0b013e31828baef9","article-title":"Update on raloxifene: Mechanism of action, clinical efficacy, adverse effects, and contraindications","volume":"68","author":"Gizzo","year":"2013","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_2","first-page":"1879","article-title":"Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)","volume":"9","author":"Fujiwara","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ajhp\/57.18.1669","article-title":"Raloxifene hydrochloride","volume":"57","author":"Snyder","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejps.2017.11.026","article-title":"Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride","volume":"112","author":"Varshosaz","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/156720109789941632","article-title":"Effectiveness of various drug carriers in controlled release formulations of raloxifene HCl prepared by melt mixing","volume":"6","author":"Bikiaris","year":"2009","journal-title":"Curr. Drug Deliv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejpb.2013.12.015","article-title":"Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanism","volume":"87","author":"Ravi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_7","first-page":"3787","article-title":"Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: Optimization and in vivo appraisal","volume":"7","author":"Elsheikh","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s11095-015-1827-7","article-title":"Glucose-based mesoporous carbon nanospheres as functional carriers for oral delivery of amphiphobic raloxifene: Insights into the bioavailability enhancement and lymphatic transport","volume":"33","author":"Ye","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s13346-018-0514-8","article-title":"Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes","volume":"8","author":"Jain","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/02652048.2014.885603","article-title":"Poly (epsilon-caprolactone) nanocapsules for oral delivery of raloxifene: Process optimization by hybrid design approach, in vitro and in vivo evaluation","volume":"31","author":"Aditya","year":"2014","journal-title":"J. Microencapsul."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.apt.2012.09.002","article-title":"Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles","volume":"24","author":"Burra","year":"2013","journal-title":"Adv. Powder Technol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/17425247.2013.745509","article-title":"Paracellular drug absorption enhancement through tight junction modulation","volume":"10","author":"Lemmer","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_14","first-page":"117","article-title":"Phase solubility techniques","volume":"4","author":"Higuchi","year":"1965","journal-title":"Adv. Anal. Chem. Instrum."},{"key":"ref_15","first-page":"791","article-title":"Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug\/HP-beta-cyclodextrin inclusion complexes","volume":"70","author":"Lu","year":"2015","journal-title":"Pharmazie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejpb.2017.10.010","article-title":"Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect","volume":"122","author":"Xie","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ijpharm.2015.10.011","article-title":"Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material","volume":"495","author":"Li","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2013.01.013","article-title":"Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent","volume":"443","author":"Tran","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijbiomac.2018.02.002","article-title":"Development of Enteromorpha prolifera polysaccharide-based nanoparticles for delivery of curcumin to cancer cells","volume":"112","author":"Li","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1021\/acs.jafc.7b05083","article-title":"Polyelectrolyte complex nanoparticles from chitosan and acylated rapeseed cruciferin protein for curcumin delivery","volume":"66","author":"Wang","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Silva, M.M., Calado, R., Marto, J., Bettencourt, A., Almeida, A.J., and Goncalves, L.M.D. (2017). Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration. Mar. Drugs, 15.","DOI":"10.3390\/md15120370"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1208\/s12248-015-9723-y","article-title":"Scientific and regulatory standards for assessing product performance using the similarity factor, f2","volume":"17","author":"Stevens","year":"2015","journal-title":"AAPS J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2014.10.038","article-title":"Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-beta-cyclodextrin","volume":"477","author":"Liu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1208\/s12249-015-0363-4","article-title":"Nanosuspensions containing oridonin\/HP-beta-cyclodextrin inclusion complexes for oral bioavailability enhancement via improved dissolution and permeability","volume":"17","author":"Zhang","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_25","first-page":"368","article-title":"Predicting human intestinal permeability using single-pass intestinal perfusion in rat","volume":"10","author":"Valizadeh","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2015.04.025","article-title":"Improving oral drug bioavailability with polycations?","volume":"97","author":"Schulz","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.trsl.2012.03.002","article-title":"Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment","volume":"160","author":"Mrhar","year":"2012","journal-title":"Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/138920021603150812121453","article-title":"Lipid-based formulations for oral drug delivery: Effects on drug absorption and metabolism","volume":"16","author":"Zhu","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2017.04.013","article-title":"Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake","volume":"117","author":"Baek","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/10\/3\/76\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:29Z","timestamp":1760195429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/10\/3\/76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["pharmaceutics10030076"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics10030076","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]}}}